Detalhe da pesquisa
1.
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 26(6): 465-e917, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469991
2.
Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials.
Clin Trials
; 18(1): 51-60, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998522
3.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162804
4.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 20(4): 518-530, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30857956
5.
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Pharmacogenet Genomics
; 29(6): 123-131, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30889042
6.
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Oncologist
; 24(7): 921-932, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30552157
7.
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
BMC Cancer
; 19(1): 1032, 2019 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31675952
8.
Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.
Int J Cancer
; 142(7): 1322-1331, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29168174
9.
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
Br J Cancer
; 119(12): 1451-1455, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30487637
10.
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Br J Cancer
; 118(7): 938-946, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527010
11.
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Oncologist
; 23(7): 782-790, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572245
12.
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
Invest New Drugs
; 36(4): 683-695, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29508247
13.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275117
14.
Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.
Radiology
; 285(1): 311-318, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28787261
15.
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Cancer
; 121(9): 1405-13, 2015 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25641662
16.
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Support Care Cancer
; 23(5): 1311-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341548
17.
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
Invest New Drugs
; 32(6): 1258-68, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25152243
18.
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
Invest New Drugs
; 32(5): 851-9, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24994097
19.
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Invest New Drugs
; 32(5): 937-45, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916770
20.
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Invest New Drugs
; 32(2): 330-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24173967